Physician profile
Neil Vyas
NPI 1447678917
$6,542.65
in general payments reported to CMS, 2019-2025
20 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $208 · 2021: $792 · 2022: $831 · 2023: $1,071 · 2024: $356 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $1,338 · Travel and Lodging: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $1,337.80 |
| Travel and Lodging | $356.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,031.50 | 2019-2025 | Orise, Resolution 360 Clip, General - Therapies |
| Olympus Medical Systems Corporation | $2,000.00 | 2025 | Evis Exera II Ultrasound Gastrovideoscope |
| Olympus America INC. | $936.57 | 2019-2024 | Single Use Electrosurgical Knife Kd-655 |
| Medtronic, INC. | $428.36 | 2023-2024 | Gi Genius, Endoflip, Manoscan |
| Apollo Endosurgery US INC | $248.20 | 2023 | Overstitch Endoscopic Suturing System |
| Fujifilm Healthcare Americas Corporation | $219.73 | 2021-2022 | |
| Abbvie INC. | $201.24 | 2019-2025 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.94 | 2019 | |
| Conmed Corporation | $108.68 | 2021 | |
| Csl Behring | $29.28 | 2023 | Kcentra |
| Madrigal Pharmaceuticals | $27.79 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $27.18 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $24.94 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $20.20 | 2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $19.72 | 2025 | Eohilia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $19.15 | 2023 | Ibsrela |
| Shionogi INC | $17.52 | 2019 | |
| Janssen Biotech, INC. | $16.29 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $14.69 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $14.67 | 2023 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.